Starsource Multitrade Ltd
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
- Market Cap ₹ 14.3 Cr.
- Current Price ₹ 95.5
- High / Low ₹ 153 / 88.0
- Stock P/E
- Book Value ₹ 9.60
- Dividend Yield 0.00 %
- ROCE 5.17 %
- ROE 3.47 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 9.95 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 27.9%
- Company has a low return on equity of 4.57% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -12 |
| OPM % | -2,234% | ||||||||||||
| 0 | 0 | 0 | 6 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | -0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | -12 |
| Tax % | 19% | 26% | 31% | 12% | 86% | 19% | 16% | 19% | -56% | 38% | 27% | 33% | |
| 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -12 | |
| EPS in Rs | 1.60 | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.00 | 2.27 | -80.93 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 1% |
| 3 Years: | 6% |
| TTM: | -3135% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 36% |
| 3 Years: | 38% |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 5% |
| Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 3 | 4 | 4 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 | 12 | -0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Total Liabilities | 5 | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 | 2 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | 0 | 0 |
| 4 | 4 | 4 | 11 | 10 | 10 | 11 | 11 | 9 | 9 | 9 | 13 | 2 | |
| Total Assets | 5 | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 | 2 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -0 | 6 | -2 | -5 | 5 | -0 | -0 | -1 | 1 | -0 | |
| 0 | 0 | 0 | 1 | 1 | 1 | 1 | -0 | 1 | 1 | -1 | 10 | |
| 0 | 0 | 0 | -0 | 1 | 0 | 0 | 2 | -2 | -0 | -0 | -0 | |
| Net Cash Flow | -0 | 0 | 0 | 6 | 1 | -5 | 6 | 1 | -1 | -0 | 0 | 10 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | 7% | 8% | 6% | 4% | 8% | 3% | 5% | 3% | 1% | 1% | 13% | 5% |
Documents
Announcements
-
Revised Outcome Of Board Meeting Held On February 12, 2026
16 Feb - Unaudited standalone and consolidated Q3/9M results for period ended Dec 31, 2025; meeting Feb 12, 2026; limited review taken on record." , "checklist": [ "Read …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Feb - Newspaper publication regarding unaudited quarterly Financial Results for the quarter and nine months ended December 31, 2025.
- Results For The Quarter And Nine Months Ended December 31, 2025 12 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting For Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025
12 Feb - Board approved unaudited standalone/consolidated results for quarter and nine months ended 31-Dec-2025.
-
Board Meeting Intimation for Considering And Approve The Un-Audited Financial Results For The Quarter And Nine Months Ended December 31, 2025 Along With The Limited Review Report Thereon.
9 Feb - Board meeting Feb 12, 2026 to approve unaudited results for quarter and nine months ended Dec 31, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Background[1]
The Chemo Pharma Laboratories Limited was established in 1942 and has been making pharmaceuticals and diversified into bulk drugs. However due to increase in competition and flow of new drugs, Company disposes their business and pay all its liabilities and dues. Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential. The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals.